Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) - Investment analysts at Zacks Research raised their Q1 2027 earnings per share (EPS) estimates for shares of Dr. Reddy's Laboratories in a research report issued to clients and investors on Tuesday, August 12th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.17 for the quarter, up from their previous estimate of $0.16. The consensus estimate for Dr. Reddy's Laboratories' current full-year earnings is $0.80 per share.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.18 by $0.02. Dr. Reddy's Laboratories had a return on equity of 17.25% and a net margin of 16.99%. The company had revenue of $988.82 million during the quarter, compared to analyst estimates of $88.27 billion.
RDY has been the topic of a number of other research reports. Wall Street Zen raised Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Hsbc Global Res raised Dr. Reddy's Laboratories from a "hold" rating to a "strong-buy" rating in a research report on Thursday, June 5th. Finally, HSBC upgraded Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating and lifted their price target for the company from $14.44 to $16.90 in a report on Thursday, June 5th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $16.95.
View Our Latest Analysis on RDY
Dr. Reddy's Laboratories Stock Performance
Dr. Reddy's Laboratories stock traded up $0.02 during mid-day trading on Thursday, hitting $14.28. 136,253 shares of the company's stock traded hands, compared to its average volume of 1,864,061. The firm has a 50 day moving average price of $14.81 and a 200 day moving average price of $14.00. The company has a quick ratio of 1.36, a current ratio of 1.89 and a debt-to-equity ratio of 0.01. The company has a market cap of $11.92 billion, a PE ratio of 21.61, a price-to-earnings-growth ratio of 5.60 and a beta of 0.29. Dr. Reddy's Laboratories has a one year low of $12.26 and a one year high of $16.85.
Institutional Investors Weigh In On Dr. Reddy's Laboratories
A number of large investors have recently bought and sold shares of the business. Ascent Group LLC grew its position in Dr. Reddy's Laboratories by 7.4% during the 2nd quarter. Ascent Group LLC now owns 10,885 shares of the company's stock worth $164,000 after acquiring an additional 754 shares during the last quarter. Allworth Financial LP boosted its position in Dr. Reddy's Laboratories by 28.4% in the 1st quarter. Allworth Financial LP now owns 3,504 shares of the company's stock valued at $49,000 after buying an additional 776 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its position in Dr. Reddy's Laboratories by 3.1% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 27,419 shares of the company's stock valued at $433,000 after buying an additional 831 shares during the last quarter. Bridgewater Advisors Inc. boosted its position in Dr. Reddy's Laboratories by 2.8% in the 1st quarter. Bridgewater Advisors Inc. now owns 31,973 shares of the company's stock valued at $446,000 after buying an additional 880 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its position in Dr. Reddy's Laboratories by 6.8% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 13,909 shares of the company's stock valued at $183,000 after buying an additional 883 shares during the last quarter. 3.85% of the stock is currently owned by institutional investors.
About Dr. Reddy's Laboratories
(
Get Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access